CLINICAL TRIALS PROFILE FOR NIZATIDINE
✉ Email this page to a colleague
All Clinical Trials for NIZATIDINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00373334 ↗ | Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) | Completed | Braintree Laboratories | Phase 3 | 2006-08-01 | The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year. |
| NCT00486005 ↗ | Weight Gain Management in Patients With Schizophrenia | Completed | Eli Lilly and Company | Phase 4 | 2003-02-01 | Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent adverse events, changes in vital signs, laboratory results and extrapyramidal effects. |
| NCT01161927 ↗ | Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions | Completed | Dr. Reddy's Laboratories Limited | Phase 1 | 2004-07-01 | The purpose of this study is to compare experimental evaluation of relative bioavailabilities in healthy, human subjects under non-fasting conditions. |
| NCT01161940 ↗ | Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions | Completed | Dr. Reddy's Laboratories Limited | Phase 1 | 2004-07-01 | This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited under fasting conditions |
| NCT01409395 ↗ | Drug-Drug Interaction Study With Metformin and Nizatidine | Completed | National Institute of General Medical Sciences (NIGMS) | Phase 1 | 2011-09-01 | This study will address the following question: Does nizatidine affect the pharmacokinetics of metformin in healthy volunteers? Recent studies in the Giacomini laboratory have indicated that nizatidine may block metformin elimination from the kidney by inhibiting organic cation transporter efflux of metformin. The investigators hypothesize that the co-administration of metformin and nizatidine will reduce the renal clearance (CLR) of metformin leading to increased plasma concentrations and potential risk for toxicities. Knowledge of the pharmacokinetic interaction profile of metformin with organic transporter inhibitors, such as nizatidine, is important to help develop safer more effective drug therapy with reduced side effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NIZATIDINE
Condition Name
Clinical Trial Locations for NIZATIDINE
Trials by Country
Clinical Trial Progress for NIZATIDINE
Clinical Trial Phase
Clinical Trial Sponsors for NIZATIDINE
Sponsor Name
